TOTECT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Totect, and when can generic versions of Totect launch?
Totect is a drug marketed by Clinigen and is included in one NDA.
The generic ingredient in TOTECT is dexrazoxane hydrochloride. There are six drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the dexrazoxane hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Totect
A generic version of TOTECT was approved as dexrazoxane hydrochloride by HIKMA on September 28th, 2004.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TOTECT?
- What are the global sales for TOTECT?
- What is Average Wholesale Price for TOTECT?
Summary for TOTECT
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 68 |
Clinical Trials: | 10 |
Patent Applications: | 393 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for TOTECT |
What excipients (inactive ingredients) are in TOTECT? | TOTECT excipients list |
DailyMed Link: | TOTECT at DailyMed |
![TOTECT drug patent expirations Drug patent expirations by year for TOTECT](/p/graph/s/t/TOTECT-patent-expirations.png)
![Drug Prices for TOTECT](/p/graph/drug-price/TOTECT.png)
Recent Clinical Trials for TOTECT
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
M.D. Anderson Cancer Center | Phase 2 |
Children's Oncology Group | Phase 3 |
EsPhALL network I-BFM Study Group | Phase 3 |
US Patents and Regulatory Information for TOTECT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Clinigen | TOTECT | dexrazoxane hydrochloride | INJECTABLE;INJECTION | 022025-001 | Sep 6, 2007 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TOTECT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Clinigen | TOTECT | dexrazoxane hydrochloride | INJECTABLE;INJECTION | 022025-001 | Sep 6, 2007 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TOTECT
See the table below for patents covering TOTECT around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Norway | 20014433 | ⤷ Sign Up | |
World Intellectual Property Organization (WIPO) | 0054782 | ⤷ Sign Up | |
European Patent Office | 1459752 | ⤷ Sign Up | |
Canada | 2367240 | TRAITEMENT D'EPANCHEMENT ACCIDENTEL D'ANTHRACYCLINES (TREATMENT OF ACCIDENTAL EXTRAVASATION OF ANTHRACYCLINES) | ⤷ Sign Up |
Mexico | PA01009212 | TRATAMIENTO DE LA EXTRAVASACION ACCIDENTAL DE ANTRACICLINAS. (TREATMENT OF ACCIDENTAL EXTRAVASATION OF ANTHRACYCLINES.) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |